These results suggest that while sPD-L1 levels may have specific relevance in the context of HER2+ breast cancer, the overall utility of sPD-1 and sPD-L1 as broad biomarkers in breast cancer appears to be limited. This evidence concerns the gene ERBB2 and breast carcinoma.